Lifecore Biomedical Inc (LFCR) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form S-8 - Securities to be offered to employees in employee benefit plans

Form S-8 - Securities to be offered to employees in employee benefit plans

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form POS AM - Post-Effective amendments for registration statement

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update

-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with...

Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

CHASKA, Minn., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore”), a fully integrated...

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a...

Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology

Multi-Million Dollar Development Agreement Establishes Lifecore as Lindy Biosciences’ Preferred CDMO Offers...